More Company News

HUTCHMED

Closing of investment of non-core OTC JV
29 Sep 2021Read More

HUTCHMED

Initiation of SURTORI-01 China Phase III trial
21 Sep 2021Read More

HUTCHMED

Start of Japan bridging study to support surufatinib registration for Advanced NETs
20 Sep 2021Read More

HUTCHMED

BTD in China for HMPL-689 in r/r FL
13 Sep 2021Read More

HUTCHMED

Initiation of SANOVO Phase III trial of Orpathys + Tagrisso in certain NSCLC patients
08 Sep 2021Read More

HUTCHMED

Initiation of Phase Ib/II trial of Fruquintinib + Tislelizumab in advanced TNBC or advanced EC
26 Aug 2021Read More

HUTCHMED

Strategic collaboration with Epizyme to develop and commercialize Tazverik in Greater China
09 Aug 2021Read More

HUTCHMED

H121 interims and business update
28 Jul 2021Read More

HUTCHMED

Initiation of savolitinib Phase II in MET amplified gastric cancer
28 Jul 2021Read More

HUTCHMED

Surufatinib MAA submitted and validated by EMA
16 Jul 2021Read More

1 2 3 4 5 6 … 12
Return to HUTCHMED
© 2019-22 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).